Zhejiang, China
Business Type:
Manufacturer/Factory, Trading Company
Management System Certification:
ISO 9001, GMP
Main Markets:
North America, South America, Eastern Europe, Southeast Asia, Africa, Oceania, Mid East, ...
Import & Export Mode:
Have Own Export License
OEM/ODM Availability:
Yes
OEM/ODM Service
Sample Available
Russian / Arabic Speaker

Ruxolitinib, 941678-49-5, Good Quality manufacturer / supplier in China, offering Good Quality, Low Price, Made in China, 99% Ruxolitinib CAS: 941678-49-5, Mjnc-6 Nc Single Facer Paperboard Cutter, Semi-Auto Carton Gluer Machine, Folder Guler and so on.

Gold Member Since 2015
Audited Supplier
Supplier Homepage Products API & Intermediates & Custom synthesis Good Quality, Low Price, Made in China, 99% Ruxolitinib CAS: 941678-49-5

Good Quality, Low Price, Made in China, 99% Ruxolitinib CAS: 941678-49-5

Get Latest Price
Min. Order / Reference FOB Price
1 Piece US $1/ Piece
Production Capacity: 3kg/Month
Transport Package: Aluminum Oil Bag
Payment Terms: L/C, T/T, D/P, Paypal, Money Gram, Western Union
Powder: Yes
Customized: Non-Customized
Suitable for: Elderly, Children, Adult
State: Solid
Purity: >99%
Product Name: Ruxolitinib

You Might Also Like

Loading...

Basic Info

Model NO.: 941678-49-5
CAS: 941678-49-5
Mf: C17h18n6
Trademark: ROYAL PHARM
Specification: 99%
Origin: China

Product Description



Ruxolitinib (INC424, INCB18424, trade names Jakafi and Jakavi, by Incyte Pharmaceuticals and Novartis) is a drug for the treatment of intermediate or high-risk myelofibrosis, a type of myeloproliferative disorder that affects the bone marrow.
It is also being investigated for the treatment of other types of cancer (such as lymphomas and pancreatic cancer),for polycythemia vera, for plaque psoriasis, and for alopecia areata.
Ruxolitinib is a Janus kinase inhibitor with selectivity for subtypes JAK1 and JAK2 of this enzyme. Ruxolitinib inhibits dysregulated JAK signaling associated with myelofibrosis. JAK1 and JAK2 recruit signal transducers and activators of transcription (STATs) to cytokine receptors leading to modulation of gene expression.


Ruxolitinib

Ruxolitinib;(R)-3-(4-(7H-Pyrrolo[2,3-d]pyrimidin-4-yl)-1H-pyrazol-1-yl)-3-cyclopentylpropanenitrile;(betaR)-beta-Cyclopentyl-4-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-1H-pyrazole-1-propanenitrile;1H-Pyrazole-1-propanenitrile,.beta.-cyclopentyl-4-(7H-pyrrolo[2,3-d]pyriMidin-4-yl)-,(.beta.R)-;(3R)-3-(4-(7H-pyrrolo[2,3-d]pyriMidin-4-yl)-1H-pyrazol-1-yl)-3-cyclopentylpropanenitrile;(3R)-3-cyclopentyl-3-(4-{7H-pyrrolo[2,3-d]pyriMidin-4-yl}-1H-pyrazol-1-yl)propanenitrile;INCB018424 (Ruxolitinib);Jakafi
CAS:941678-49-5

C17H18N6

306.371

Send your message to this supplier

*From:
*To:
avatar Miss Anna
*Message:

Enter between 20 to 4,000 characters.

This is not what you are looking for? Post a Sourcing Request Now